ALT正常、HBeAg阳性慢性HBV感染者如何选择合适的治疗时机?

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名

邮箱

手机号码

标题

留言内容

验证码

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：赵红负责起草文章; 谢雯负责文章修改和审校。

详细信息

How to determine the optimal treatment timing in chronic HBV infection patients with normal ALT and positive HBeAg?

Liver Disease Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

[1]	CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.
[2]	KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
[3]	LEE HW, KIM EH, LEE J, et al. Natural history of untreated HBeAg-positive chronic HBV infection with persistently elevated HBV DNA but normal alanine aminotransferase[J]. Clin Transl Gastroenterol, 2020, 11(3): e00140. DOI: 10.14309/ctg.0000000000000140.
[4]	CHANG Y, CHOE WH, SINN DH, et al. Nucleos(t)ide analogue treatment for patients with hepatitis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A nationwide, multicenter, retrospective study[J]. J Infect Dis, 2017, 216(11): 1407-1414. DOI: 10.1093/infdis/jix506.